Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of ...

In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical ...

Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...

The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...

New trial results show dupilumab significantly improves remission rates and reduces symptoms in patients with bullous ...

27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab ...

A new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) ...

The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...